Mark A Demitrack

Summary

Publications

  1. ncbi Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data
    Mark A Demitrack
    Neuronetics, Inc, Malvern, PA, USA
    Psychopharmacol Bull 42:5-38. 2009
  2. ncbi Clinical perspectives on antidepressant drug development: a critical discussion
    M A Demitrack
    Neuronetics, Inc, One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA
    Curr Pharm Des 11:227-31. 2005
  3. ncbi Clinical methodology and its implications for the study of therapeutic interventions for chronic fatigue syndrome: a commentary
    Mark A Demitrack
    Neuronetics, Inc, One Great Valley Parkway, Suite 2, Malvern, Pennsylvania 19355, USA
    Pharmacogenomics 7:521-8. 2006
  4. ncbi Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial
    David J Goldstein
    Eli Lilly and Company, and Department of Pharmacology and Toxicology, Indiana University Medical School, Indianapolis 46285, USA
    J Clin Psychiatry 63:225-31. 2002
  5. ncbi Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial
    Michael J Detke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind 46285, USA
    J Clin Psychiatry 63:308-15. 2002
  6. ncbi Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression
    Michael J Detke
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
    J Psychiatr Res 36:383-90. 2002
  7. ncbi Effects of duloxetine on painful physical symptoms associated with depression
    David J Goldstein
    Department of Psychitry adn the Department of Pharmacology adn toxicology, Indiana Unibersity School of Medicine, Indianapolis, USA
    Psychosomatics 45:17-28. 2004
  8. ncbi Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome
    Leslie J Crofford
    Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA
    Brain Behav Immun 18:314-25. 2004
  9. ncbi Can monoamine-based therapies be improved?
    Mark A Demitrack
    Lilly Research Laboratories, Lilly Corporate Center, Drop Code 2066, Indianapolis, IN 46285, USA
    J Clin Psychiatry 63:14-8. 2002

Collaborators

Detail Information

Publications9

  1. ncbi Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data
    Mark A Demitrack
    Neuronetics, Inc, Malvern, PA, USA
    Psychopharmacol Bull 42:5-38. 2009
    ..These data may be helpful in treatment-planning decisions when using TMS in clinical practice...
  2. ncbi Clinical perspectives on antidepressant drug development: a critical discussion
    M A Demitrack
    Neuronetics, Inc, One Great Valley Parkway, Suite 2, Malvern, PA 19355, USA
    Curr Pharm Des 11:227-31. 2005
    ..In this selective review, several key areas of interest relevant to the clinical development of antidepressants are examined. These areas point to some suggested topics for attention in the future...
  3. ncbi Clinical methodology and its implications for the study of therapeutic interventions for chronic fatigue syndrome: a commentary
    Mark A Demitrack
    Neuronetics, Inc, One Great Valley Parkway, Suite 2, Malvern, Pennsylvania 19355, USA
    Pharmacogenomics 7:521-8. 2006
    ..The role of clinical methodology in the study of the therapeutics of CFS is not trivial, and may confound our understanding of pragmatic recommendations for treatment...
  4. ncbi Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial
    David J Goldstein
    Eli Lilly and Company, and Department of Pharmacology and Toxicology, Indiana University Medical School, Indianapolis 46285, USA
    J Clin Psychiatry 63:225-31. 2002
    ..Duloxetine hydrochloride, a dual reuptake inhibitor of serotonin and norepinephrine, was evaluated for therapeutic efficacy and safety/tolerability in the treatment of major depression...
  5. ncbi Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial
    Michael J Detke
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind 46285, USA
    J Clin Psychiatry 63:308-15. 2002
    ..Duloxetine hydrochloride, a dual reuptake inhibitor of serotonin and norepinephrine, was evaluated for efficacy and tolerability/safety in the treatment of MDD and associated physical symptoms...
  6. ncbi Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression
    Michael J Detke
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
    J Psychiatr Res 36:383-90. 2002
    ..There was no significant incidence of hypertension, nor any other safety issues. Duloxetine 60 mg administered once daily appears to be a safe and effective treatment for MDD...
  7. ncbi Effects of duloxetine on painful physical symptoms associated with depression
    David J Goldstein
    Department of Psychitry adn the Department of Pharmacology adn toxicology, Indiana Unibersity School of Medicine, Indianapolis, USA
    Psychosomatics 45:17-28. 2004
    ..Compared with placebo, duloxetine was associated with significant reduction in pain severity. The authors concluded that duloxetine reduces the painful physical symptoms of depression...
  8. ncbi Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome
    Leslie J Crofford
    Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA
    Brain Behav Immun 18:314-25. 2004
    ..The abnormalities in FMS patients are consistent with loss of HPA axis resiliency...
  9. ncbi Can monoamine-based therapies be improved?
    Mark A Demitrack
    Lilly Research Laboratories, Lilly Corporate Center, Drop Code 2066, Indianapolis, IN 46285, USA
    J Clin Psychiatry 63:14-8. 2002
    ....